Shopping cart
No products in the cart.

A multi cancer early detection test uses next generation sequencing to detect ctDNA from the tumor cells​

Screening for 5 most common types of cancers (Breast, Liver, Lung, Stomach, Colon) with 1 simple blood draw.

ctDNA (circulating tumor DNA) is DNA released from cancerous cells and tumors, circulating freely in the bloodstream.

ctDNA analysis based on NGS is a global trend
in early cancer detection. 

ctDNA can be detected through a blood test and has been shown to be a valuable tool in the cancer early detection, especially for those healthy and asymptomatic. ​

How SPOT-MAS works


Cancerous cells are formed in the tumor


Tumor cells release DNA fragments to the bloodstream, called circulating tumor DNA (ctDNA)


Draw a blood sample (10ml) to extract cell-free DNA from plasma


Apply next-generation sequencing to detect 5 different features of ctDNA from tumor cells compared with cfDNA from normal cell

  • cDNA detected: SPOT-MAS test detected a ctDNA signal associated with cancer​
  • No ctDNA detected: The SPOT-MAS test looked for a cancer signal and did not find one at this moment.​
5 features: genome-wide methylation changes (GWM),methylation changes at 450 target regions,distinct size, copy number alterations (CNA), end - motif (EM)


ctDNA is detected will be co-analysis with prediction of tumor origins in the scope of 5 cancers, based on advance machine learning data, to guide the further steps for doctors

Understanding the results of SPOT-MAS

SPOT-MAS test result will be notified to customers after 12 – 20 days from the day when Gene Solutions’ lab received the blood sample. Test results will showcase 2 possibilities

Positive: ctDNA signal detected

  • Meaning of the SPOT-MAS test (*)
    ctDNA signal associated with tumor cancer is detected in the blood. The result will include 1-2 predictions of the origins of tumor in the body that the cancer signal may be coming from.
  • Next step:
    The ctDNA detected as cancer signal detected in the SPOT-MAS test result is not a cancer diagnosis and requires follow-up recommended diagnostic tests in guidelines, such as imaging ordered by your doctor to confirm cancer officially.

Negative: No ctDNA signal detected

  • Meaning of the SPOT-MAS test (*)​
    ctDNA is not detected at the time SPOT-MAS test is conducted (This test only screens for ctDNA in the testing range of 5 cancer types and does not assess the risk for having cancer in the future)
  • Next step:
    Continue with the SPOT-MAS test or any cancer screening every 6 months – 1 year as recommended by the healthcare expert. Do not ignore cancer signs or symptoms if they occur, as this could lead to a delayed diagnosis.

How is SPOT-MAS different from hereditary cancer screening tests?

Hereditary cancer screening tests look for genes with mutations linked to cancer risks, and do not tell whether you have cancer at the time of testing.

Scientific evidence

Clinical validation of SPOT-MAS, Cancer Investigation, 2023

cfDNA enabling large-scale profile of lung cancer patients, Frontiers in Oncology, 2020

Liquid-biopsy and ctDNA methylation, PLOS ONE, 2019

What experts say

Tran Le Son, PhD.

ctDNA technology enables multi-cancer early detection (MCED) through a single blood draw. Non-invasive, convenient, accurate and accessible, the test is very promising in opening a new era in the world’s fight against cancer.

Nguyen Duy Sinh, MD

Cancer cells may develop so silently within our body for as long as 12 years without patients being aware of any symptom, until it is too late. Therefore, detecting cancer at early stages determines the efficacy of treatment.

of the SPOT-MAS test


of the most common types of cancer*

Proven accuracy

The accuracy in early cancer detection and tumor origin prediction are validated in clinical studies

The licensed SPOT-MAS test is a supportive screening one, and does not replace current cancer screening guidelines.

Routine screening methods:

Breast cancer:

X-ray & Mammogram

Liver cancer:


Lung cancer:

Low-dose CT (imaging)

Colorectal cancer:


Stomach cancer:


If you would like to know more about these tests, please contact nearby hospitals or clinics for more details.

Who should take
the SPOT-MAS test?

Recommended for:

Not recommended for:

​(*) Smoking more than 20 packs/year or passive smokers;

who drink more than 15 cans/week for men and eight cans/week for women; 

people who are constantly exposed to toxic substances or a polluted environment.

 (**) Family history of having been diagnosed with cancer.​

Schedule a consultation

Important Safety Infomation SPOT-MAS

The SPOT-MAS test is recommended for use in adults with elevated risk of cancer, such as those aged 40 years or older, those who carry genetic mutations, or those with unhealthy habits like smoking, drinking alcohol, getting hepatitis B, C. SPOT-MAS is not recommended for pregnant women or patients undergoing cancer treatment, or those with the history of bone marrow transplant, blood transfusion within 3 months.

The SPOT-MAS test is used to detect signals that suggest cancer through ctDNA released from cancer cells into the bloodstream and to predict the tumor origin of the cancer signal in the body. SPOT-MAS does not detect all cancers and not all cancers can be detected through ctDNA analysis. Therefore, SPOT-MAS should be used as recommended by the Doctor and as a supporting method for recommended routine cancer screening methods to help detect cancer EARLY.​

It should be noted that SPOT-MAS is a screening test and SPOT-MAS results should be consulted by a healthcare expert, or a genetic specialist. The Doctor will interpret the results of the SPOT-MAS test based on information of your medical history, clinical symptoms, and other signals. A negative SPOT-MAS test result “no ctDNA signal detected” does not exclude all possibilities of having cancer, so it is still necessary for the routine check-up of cancer as recommended by a healthcare professional. With a positive SPOT-MAS test result “ctDNA signal detected” and the origin of cancer prediction, the Doctor will recommend follow-up diagnostic methods such as imaging, biopsy, etc. to confirm the presence of cancer. False positives and false negatives do occur.​

When using SPOT-MAS tests for early cancer screening, some limitations of ctDNA analysis method released from cancer cells into peripheral blood should be kept in mind about the following results:​

  • A negative result (no ctDNA signal yet) does not completely exclude the presence of cancer because the tumor might be out of the screening range (5 types) or located in the location where it is difficult for ctDNA to release, or the secondary cancer has completely different methylation changes than the primary cancer.​
  • The sensitivity is 72.4%, meaning that for every 100 cases of cancer, about 28 cases will be missed. It is recommended that this test should be used as an adjunct to screening, not a substitute for current recommended routine cancer screening methods.​
  • A positive result (ctDNA signal detected) does not completely confirm that the participant has cancer due to some special physiological or pathological circumstances can produce a “false positive” result. The specificity is 97%, which means that for every 100 cancer-free cases, about 3 will have positive to ctDNA signals.​
  • The positive predictive value of the test is 58.1%, which means that for every 100 cases that are positive, 60 will have cancer. Therefore, a positive result should be consulted by an oncologist, genetic specialist and confirmed with medical imaging tests.​
  • The tumor origin is predicted based on machine learning algorithms that analyze 4 different features of ctDNA released to the bloodstream and predict the tumor origins with the accuracy of 84%. However, these features of ctDNA can be duplicated leading to the inability to completely identify the tumor origin.​


*According to the report of GLOBOCAN 2020, the 5 most common types of cancer in Vietnam include liver cancer (14.5%), lung cancer (14.4%), breast cancer (11.8%), %), stomach cancer (9.8%) and colorectal cancer (9%).​​

**According to Cancer Investigation (USA) , a research published by Gene Solutions in February 2023 on 2,975 people taking SPOT-MASTM cancer screening test. The test shows its sensitivity of 73.9%, specificity of 95.9%, positive predictive value (PPV) 58.1%, tumor tissue of origin (TOO) 84% ​

GENE SOLUTIONS experts are listening to you!


Tư vấn di truyền